Nasdaq

Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies

CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
EurekAlert!

Complement system response to AAV vector gene therapy

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...
News Medical

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Nature

Brain engraftment of autologous macrophages transduced with a lentiviral flap vector: an approach to complement brain dysfunctions

The transfer of therapeutic genes into CNS-homing cells is a promising approach for brain therapy. Numerous cell types such as neural progenitors, astrocytes, fibroblasts and immortalized cells have ...